306935-14-8

Basic information

• Product Name: 3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE
• Synonyms: 3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE;3-Phenyl-5-piperazino-1,2,4-thiadiazole 97%;3-Phenyl-5-piperazin-1-yl-1,2,4-thiadiazole;3-Phenyl-5-piperazin-1-yl-1,2,4-thiadiazole 97%;1-(3-Phenyl-1,2,4-thiadiazol-5-yl)piperazine 97%;1-(3-Phenyl-1,2,4-thiadiazol-5-yl)piperazine97%
• CAS NO: 306935-14-8
• Molecular Formula: C₁₂H₁₄N₄S
• Molecular Weight: 246.33
• Mol File: 306935-14-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 91-93
• Boiling Point: 415.9°C at 760 mmHg
• Flash Point: 205.3°C
• Appearance: /
• Density: 1.238 g/cm³
• Vapor Pressure: 3.99E-07mmHg at 25°C
• Refractive Index: 1.609
• PKA: 8.27±0.10(Predicted)
• CAS DataBase Reference: 3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE(306935-14-8)
• EPA Substance Registry System: 3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE(306935-14-8)

Safety Data

• Hazard Codes: C,T
• Statements: 36/37/38-25
• Safety Statements: 26-36/37/39-45
• HazardClass: IRRITANT
• Hazardous Substances Data: 306935-14-8(Hazardous Substances Data)

Usage

General Description

3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE is an organic chemical compound with the molecular formula C14H15N5S. It belongs to the class of 1,2,4-thiadiazoles, which are a group of heterocyclic compounds containing a five-membered ring with two nitrogen atoms and one sulfur atom. 3-PHENYL-5-PIPERAZINO-1,2,4-THIADIAZOLE has a phenyl group and a piperazine ring attached to the thiadiazole ring, and it is commonly used as a pharmaceutical intermediate for the synthesis of various drugs. It exhibits potential pharmacological activities, including antimicrobial, anticonvulsant, antidepressant, and antitumor properties. Its unique molecular structure and diverse biological activities make it an important chemical compound in the field of medicinal chemistry and drug development.

InChI:InChI=1/C12H14N4S/c1-2-4-10(5-3-1)11-14-12(17-15-11)16-8-6-13-7-9-16/h1-5,13H,6-9H2

Upstream product

• 887623-99-6 tert-butyl 4-(3-phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxylate 
• 1670-14-0 benzamidine monohydrochloride 
• 24255-23-0 5-chloro-3-phenyl-[1,2,4]thiadiazole 
• 110-85-0 piperazine 
• 594-42-3 chlorothio-trichloro-methane 

Downstream Products

• 331767-52-3 9-{4-[4-(3-phenyl-[1,2,4]thiadiazol-5-yl)-piperazin-1-yl]-butyl}-9H-fluorene-9-carboxylic acid-(2,2,2-trifluoroethyl)-amide 
• 874646-44-3 (5S)-2,2-dimethyl-5-((1S)-3-methyl-1-{[4-(3-phenyl-1,2,4-thiadiazol-5-yl)-1-piperazinyl]carbonyl}butyl)-1,3-dioxolan-4-one 
• 1062511-99-2 C₂₀H₁₈F₃N₅O₂S 
• 1062512-20-2 C₁₇H₁₈N₆OS₂ 
• 1062512-16-6 C₂₂H₂₁N₇OS 
• 1062512-07-5 C₁₈H₁₉N₇O₂S 
• 1062512-09-7 C₁₈H₁₆N₈OS 
• 1062512-10-0 C₁₇H₁₆ClN₇OS 
• 1062512-11-1 C₁₆H₁₆N₈OS 
• 1062512-13-3 C₁₉H₁₇N₇OS₂ 
• 1062512-18-8 C₂₂H₂₀N₆OS₂ 
• 887622-82-4 C₁₄H₁₅N₉OS 
• 681136-26-5 C₂₀H₁₈F₃N₅OS₂ 
• 681136-27-6 C₂₀H₁₈F₃N₅O₂S 

Relevant articles and documents

The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119

A series of xanthine compounds derived from the previous hit 20i with modification on the terminal side chain was discovered through ring formation strategy. Systematic optimization of the compounds with rigid heterocycles in the hydrophobic side chain led to the new lead compound HBK001 (21h) with the improved DPP-IV inhibition and moderate GPR119 agonism activity in vitro. As a continuing work to further study the PK and PD profiles, 21h and its hydrochloride (22) were synthesized on grams scale and evaluated on the ADME/T and oral glucose tolerance test (OGTT) in ICR mice. Compound 22 showed the improved bioavailability and blood glucose-lowering effect in vivo compared to its free base 21h probably attributed to its improved solubility and permeability. The preliminary toxicity studies on compound 22 exhibited that the result of mini-Ames was negative and the preliminary acute toxicity LD50 in mice was above 1.5 g/kg, while it showed moderate inhibition on hERG channel with IC50 4.9 μM maybe due to its high lipophilicity. These findings will be useful for the future drug design for more potent and safer dual ligand targeting DPP-IV and GPR119 for the treatment of diabetes.

Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase

A series of thiadiazolopiperazinyl aryl urea fatty acid amide hydrolase (FAAH) inhibitors is described. The molecules were found to inhibit the enzyme by acting as mechanism-based substrates, forming a covalent bond with Ser241. SAR and PK properties are